Oxana Denisova receives 30 000 grant from Aamu foundation
Oxana Denisova receives 30 000 grant from Aamu foundation for her research on ‘PP2A in medulloblastoma therapy resistance: novel opportunities for targeted therapeutics.’
– My current research interest belongs to a field of brain cancer resistance and anticancer therapy development, particularly I focus on a role of protein phosphatase 2A (PP2A) and its inhibitor proteins in glioblastoma and pediatric medulloblastoma. I recently demonstrated that combination of PP2A reactivation and multi-kinase inhibition results in profound synergistic cell killing of adult glioblastoma and medulloblastoma cells, Oxana tells.
Recent Posts
- Turku Protein Core Opens Two New PositionsTurku Protein Core (TuProtCore) is seeking to fill two roles: a Project Specialist in Service Read moreApril 7, 2026
- The Jane and Aatos Erkko Foundation has granted nearly €1 million to support research led by Professor Jukka Westermarck993 000 € was granted to a research project led by our Group Leader Professor Jukka Read moreApril 2, 2026
- Cecilia Sahlgren’s group discovers a new mechanism driving breast cancer progressionOur affiliated research group led by Professor Cecilia Sahlgren at Åbo Akademi University and the InFLAMES Research Read moreMarch 25, 2026
- BioCity Turku asks for proposals for Elias Tillandz publication prize winner during March 2026In the context of the 35th BioCity Symposium “Vision, Expanded” (27-28 August 2026) the twenty-second Read moreMarch 3, 2026
- Rector Widen Visited Our Centre Åbo Akademi University Rector, Gunilla Widén, visited our Centre on Wednesday, February 25th, to learn Read moreFebruary 27, 2026
- Laura Elo is awarded the Leif C. Groop Award for outstanding research on type 1 diabetesLaura Elo a group leader at Turku Bioscience is awarded the Leif C. Groop Award Read moreFebruary 23, 2026